Corporate Profile for VIVUS, Inc., dated Aug. 11, 1995.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and information services See Information Systems. . These include Dow Jones News/Retrieval, Bloomberg Financial Markets, Reuter Company Newsyear, Reuter Business Briefing, DataTimes, Nexis, Dialog, NewsNet, America OnLine, CompuServe, Delphi, Individual's HeadsUp and First!, Desktop Data's NewsEdge, UMI UMI University Microfilms International UMI United States Minor Outlying Islands (ISO Country code) UMI University of Miami UMI Universal Management Infrastructure (IBM) Data Courier, NewsBank, Information Access Company and many others. -0- Published date: Aug. 11, 1995 Company name: VIVUS, Inc.
Address: 545 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone No.: 415/325-5511 Fax No.: 415/325-5546 Chief Executive Officer: Leland F. Wilson, President and CEO Chief Financial Officer: David C. Yntema, Vice President of Finance and CFO Investor Relations Contact: Barbara S. Clark Business number: 415/325-5511 Trading symbol: VVUS Industry: Pharmaceutical Company description: VIVUS, Inc., founded in 1991, is a development-stage pharmaceutical company dedicated to becoming a world leader in providing effective pharmacological treatments for male erectile dysfunction Erectile Dysfunction Definition Erectile dysfunction (ED), formerly known as impotence, is the inability to achieve or maintain an erection long enough to engage in sexual intercourse. (impotence). The company's technology, MUSE(R) (Medicated medicated /med·i·cat·ed/ (med´i-kat?id) imbued with a medicinal substance. medicated contains a medicinal substance. Urethral urethral pertaining to or emanating from urethra. urethral agenesis, urethral atresia failure of development of all or part of the urethra: characterized by complete urine retention. A rare cause of neonatal uremia. System for Erection), is based on the discovery that the urethra urethra (y  rē`thrə), canal in most mammals that carries urine from the bladder to the outside of the body; in the male it also serves as a genital duct. , although an
excretory duct, can absorb certain pharmacologic agents into the
surrounding erectile tissues. Intraurethral delivery constitutes a
radical departure from the other therapies currently in use.The pharmacologic agent in VIVUS' first product is alprostadil, the generic name for the synthetic version of prostaglandin E1, a naturally occurring vasodilator vasodilator /vaso·di·la·tor/ (-di-la´ter) 1. causing dilatation of blood vessels. 2. a nerve or agent that does this. va·so·di·la·tor n. . Alprostadil administered by needle injection to the penis was approved for use in the treatment of erectile dysfunction by the U.S. FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. in July 1995. The MUSE system consists of a small, single-use, disposable plastic applicator ap·pli·ca·tor n. An instrument for applying something, such as a medication. applicator, n a device for applying medication; usually a slender rod of glass or wood, used with a pledget of cotton on the end. that contains the pharmacologic agents. The end of the applicator, about 3.5 millimeters in diameter, is inserted about three centimeters (just over an inch) into the urethra, where the medication is released. An erectile response is generally produced within minutes of administration and lasts for about 30 to 60 minutes. The U.S. Phase III clinical studies for VIVUS' first product, MUSE-alprostadil, were completed in July 1995. VIVUS expects to file a New Drug Application with the FDA in early 1996. VIVUS reported a net loss of $11.9 million for the six months ended June 30, 1995. The company had more than $50 million in cash, cash equivalents and available-for-sale securities at June 30, 1995. CONTACT: VIVUS, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion